ABHD5 and cancer: Collectively, these experiments identified a novel regulatory cascade through which activation of ABHD5 inhibits cancer anabolism by creating a futile cycle of TG hydrolysis and synthesis that activates AMPK and subsequently inhibits mTORC1.